3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
NIH
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Conditions
Lung Neoplasms
29
Ovarian Neoplasms
27
Fallopian Tube Neoplasms
24
Carcinoma, Non-Small-Cell Lung
23
Colorectal Neoplasms
16
Melanoma
12
Carcinoma, Renal Cell
12
Carcinoma, Hepatocellular
12
Squamous Cell Carcinoma of Head and Neck
11
Pancreatic Neoplasms
11
Glioblastoma
11
Breast Neoplasms
11
Triple Negative Breast Neoplasms
10
Urinary Bladder Neoplasms
8
Prostatic Neoplasms
8
Neoplasm Metastasis
8
Uterine Cervical Neoplasms
7
Brenner Tumor
7
Mycosis Fungoides
6
Colonic Neoplasms
6
Brain Neoplasms
6
Rectal Neoplasms
5
Multiple Myeloma
5
Lymphoma, T-Cell, Cutaneous
5
Endometrial Neoplasms
5
Sezary Syndrome
4
Sarcoma
4
Neoplasms
4
Nasopharyngeal Carcinoma
4
Lymphoma, Large B-Cell, Diffuse
4
Interventions
Imatinib Mesylate
67
Sunitinib
27
nilotinib
14
regorafenib
13
ripretinib
10
avapritinib
5
Ipilimumab
5
Dasatinib
5
spartalizumab
4
Laparoscopy
4
CTLA-4 Antigen
4
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
4
pexidartinib
3
pazopanib
3
binimetinib
3
Temozolomide
3
Paclitaxel
3
Oxaliplatin
3
Nivolumab
3
Midazolam
3
Leucovorin
3
Gemcitabine
3
Bevacizumab
3
trametinib
2
tanespimycin
2
ponatinib
2
pembrolizumab
2
masitinib
2
famitinib
2
envafolimab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Gastrointestinal Stromal Tumors
×
Immunoglobulin G
×
Clear all
NCT00324987
2017-09-14
S0502
National Cancer Institute (NCI)
Phase 3
Terminated
12 enrolled
13 charts